Panel discussions
The ADC industry is undergoing unprecedented growth, propelled by cutting-edge innovations and a wave of high-profile collaborations between multinational corporations (MNCs) and pioneering biotechs. Landmark deals such as Pfizer’s $43 billion acquisition of Seagen, AbbVie’s $10 billion purchase of ImmunoGen, Genmab’s $1.8 billion acquisition of the Chinese biotech ProfoundBio and Merck’s potential $22 billion partnership with Daiichi Sankyo exemplify this trend, with investments surpassing $100 billion in partnerships and M&A since 2019. These alliances are accelerating the development of ADC therapies, blending scientific ingenuity with therapeutic promise. Yet, their success depends on robust Chemistry, Manufacturing, and Controls (CMC) development, which ensures product quality, scalability, and regulatory compliance—critical pillars that transform innovative concepts into market-ready solutions. In this panel, we will examine how licensing, NewCo formation, and strategic partnerships are reshaping the ADC landscape and why high quality CMC is critical for the success of partnership deals during due diligence and post-deal product development.
May 6, 14:00 - 14:45, room Marriott 1+2
| Name | Position | Institution |
|---|---|---|
| Dr. Jimmy Li | CEO | WuXi XDC |
| Name | Position | Institution |
|---|---|---|
| Dr. Ulf Grawunder | CEO | T-Curx |
| Dr. Dominik Escher | Managing Partner | Pureos Bioventures |
| TBD | Big Pharma BD Executive | |
| TBD | Biotech CEO |
WuXi XDC （ 2268.HK ） is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products.
